In a report released on December 28, Marie Thibault from BTIG maintained a Hold rating on Venus Concept (VERO – Research Report). The company’s shares closed last Friday at $1.18.
Thibault covers the Healthcare sector, focusing on stocks such as Inari Medical, Atricure, and Insulet. According to TipRanks, Thibault has an average return of -1.8% and a 35.26% success rate on recommended stocks.
Venus Concept has an analyst consensus of Moderate Buy, with a price target consensus of $10.60.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.01 and a one-year low of $0.87. Currently, Venus Concept has an average volume of 8,505.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Venus Concept (VERO) Company Description:
Venus Concept, Inc. is a medical aesthetic technology company. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded in 2002 and is headquartered in Toronto, Canada.
Read More on VERO:
- Venus Concept expands international distributor network
- Venus Concept Announces New International Distributors in the United Kingdom and India to Continue Global Growth
- Venus Concept files to sell 1.23M shares of common stock for holders
- Venus Concept price target lowered to $10.60 from $11 at Ladenburg
- Venus Concept backs FY23 revenue view 80M-$82M, consensus $80.69M
